Movement Disorders:路易体病理和阿尔兹海默病理,如何影响男女的临床表型差异?

2022-05-29 网络 网络

使用LB和AD生物标志物,即使在LB或AD病理不在临床预期之内,对于LB疾病和AD的准确临床诊断也是必要的。

继阿尔茨海默病(AD)之后,路易体(LB)疾病是第二种最常见的神经退行性痴呆疾病,包括帕金森病、帕金森病痴呆和路易体痴呆。这些疾病有一系列重叠的临床特征、遗传风险因素,以及α-突触核蛋白阳性的路易体和路易体神经元的共同神经病理学特征。

 

图1: 论文封面图

目前,神经病理学确认仍然是诊断LB病的金标准,而对有LBs的痴呆和早期帕金森病的临床诊断准确率仍然只有50%左右,这大大限制了将早期患者分配到疾病改良剂临床试验中的努力。 在那些同时患有LB和AD病症的患者中,较高的神经纤维缠结负担与较低的LB痴呆临床诊断的可能性有关,这可能是因为相关的认知特征的改变和较低的LB核心特征如视幻觉的可能性。

性别也与纯LB病理者的表型差异以及LB病理者的AD共病理的频率有关。与男性相比,混合LB和AD病理在女性中更常见,而纯LB病理不太可能导致LB临床表型,在女性中更可能出现AD临床表型。在AD中,女性比男性有更大的tau负担,有类似的认知障碍,而且女性在发展认知衰退之前可以承受更多的tau。 然而,在有LB病理的人中,性别和AD共病理学,特别是tau的交互影响仍然未知。

藉此,加州大学圣地亚哥的Ece Bayram等人,利用国家阿尔茨海默氏症协调中心(NACC)收集的大规模、多中心的尸检验证个体数据,分析了AD共病理学和LB疾病核心临床特征之间的性别差异,包括认知波动、视觉幻觉、快速眼动睡眠行为障碍(RBD)和帕金森症。

还评估了性别特异性Braak tau分期与临床特征的关系。由于LB痴呆症患病率的性别差异可能取决于年龄,70-75岁以下的男性患病率较高,女性患病率随年龄增长而增加,通过对年龄分层组的额外分析调查了年龄的影响。

核心假设,那些有更多AD病理的人将不太可能有LB临床表型,而且与男性相比,女性对LB病理患者的误诊率会更高。

该研究的数据来自国家阿尔茨海默病协调中心,有223名女性和468名男性肢体或新皮层LB患者,根据病理学分为两组,即LB临床表型的高可能性和低/中可能性。分析了性别的临床关联以及性别和病理学对临床表型的交互作用。

他们发现:更严重的AD共病理学与更差的认知衰退和较低的LB疾病临床表型的可能性有关。

 


图2:论文结果图


与男性相比,具有更严重的AD共病理学和tau的女性有更差的认知衰退和更高的AD临床表型的可能性。

 

与女性相比,具有更严重的AD共病理学的男性具有较低的LB临床表型的可能性。性别和病理的相互作用在70-80岁之间的人中更为明显。

AD共病理学降低了女性和男性出现LB临床表型的可能性;然而,男性可能有较高的LB疾病诊断不足的风险,女性则有较高的痴呆风险。使用LB和AD生物标志物,即使在LB或AD病理不在临床预期之内,对于LB疾病和AD的准确临床诊断也是必要的。

 

原文出处:

Bayram E, Coughlin DG, Litvan I. Sex Differences for Clinical Correlates of Alzheimer’s Pathology in People with Lewy Body Pathology. Movement Disorders. Published online May 9, 2022:mds.29044. doi:10.1002/mds.29044

 

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1784502, encodeId=f5b31e845027b, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Sat Oct 15 05:05:44 CST 2022, time=2022-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878522, encodeId=cf8018e852248, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Thu Nov 24 05:05:44 CST 2022, time=2022-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754961, encodeId=314c1e54961a2, content=<a href='/topic/show?id=bf6093140d4' target=_blank style='color:#2F92EE;'>#路易体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93140, encryptionId=bf6093140d4, topicName=路易体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=576436807451, createdName=longerg, createdTime=Fri Feb 17 21:05:44 CST 2023, time=2023-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013883, encodeId=a69420138833f, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Mar 24 16:05:44 CST 2023, time=2023-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077687, encodeId=11f420e76871a, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Thu Dec 08 18:05:44 CST 2022, time=2022-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738120, encodeId=097e1e3812015, content=<a href='/topic/show?id=e10b600329' target=_blank style='color:#2F92EE;'>#disorders#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6003, encryptionId=e10b600329, topicName=disorders)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Mon Oct 03 23:05:44 CST 2022, time=2022-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402848, encodeId=66fd1402848c3, content=<a href='/topic/show?id=60ca9e761ce' target=_blank style='color:#2F92EE;'>#阿尔兹海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97761, encryptionId=60ca9e761ce, topicName=阿尔兹海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be952422716, createdName=habb, createdTime=Sat May 28 12:05:44 CST 2022, time=2022-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487161, encodeId=6ee3148e1614c, content=<a href='/topic/show?id=5b8d2299977' target=_blank style='color:#2F92EE;'>#临床表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22999, encryptionId=5b8d2299977, topicName=临床表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70ff8274322, createdName=hukaixun, createdTime=Sat May 28 12:05:44 CST 2022, time=2022-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535334, encodeId=7e7d153533453, content=<a href='/topic/show?id=099f9020145' target=_blank style='color:#2F92EE;'>#表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90201, encryptionId=099f9020145, topicName=表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6412593156, createdName=tastas, createdTime=Sat May 28 12:05:44 CST 2022, time=2022-05-28, status=1, ipAttribution=)]
    2022-10-15 cmsvly
  2. [GetPortalCommentsPageByObjectIdResponse(id=1784502, encodeId=f5b31e845027b, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Sat Oct 15 05:05:44 CST 2022, time=2022-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878522, encodeId=cf8018e852248, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Thu Nov 24 05:05:44 CST 2022, time=2022-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754961, encodeId=314c1e54961a2, content=<a href='/topic/show?id=bf6093140d4' target=_blank style='color:#2F92EE;'>#路易体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93140, encryptionId=bf6093140d4, topicName=路易体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=576436807451, createdName=longerg, createdTime=Fri Feb 17 21:05:44 CST 2023, time=2023-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013883, encodeId=a69420138833f, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Mar 24 16:05:44 CST 2023, time=2023-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077687, encodeId=11f420e76871a, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Thu Dec 08 18:05:44 CST 2022, time=2022-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738120, encodeId=097e1e3812015, content=<a href='/topic/show?id=e10b600329' target=_blank style='color:#2F92EE;'>#disorders#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6003, encryptionId=e10b600329, topicName=disorders)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Mon Oct 03 23:05:44 CST 2022, time=2022-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402848, encodeId=66fd1402848c3, content=<a href='/topic/show?id=60ca9e761ce' target=_blank style='color:#2F92EE;'>#阿尔兹海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97761, encryptionId=60ca9e761ce, topicName=阿尔兹海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be952422716, createdName=habb, createdTime=Sat May 28 12:05:44 CST 2022, time=2022-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487161, encodeId=6ee3148e1614c, content=<a href='/topic/show?id=5b8d2299977' target=_blank style='color:#2F92EE;'>#临床表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22999, encryptionId=5b8d2299977, topicName=临床表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70ff8274322, createdName=hukaixun, createdTime=Sat May 28 12:05:44 CST 2022, time=2022-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535334, encodeId=7e7d153533453, content=<a href='/topic/show?id=099f9020145' target=_blank style='color:#2F92EE;'>#表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90201, encryptionId=099f9020145, topicName=表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6412593156, createdName=tastas, createdTime=Sat May 28 12:05:44 CST 2022, time=2022-05-28, status=1, ipAttribution=)]
    2022-11-24 anminleiryan
  3. [GetPortalCommentsPageByObjectIdResponse(id=1784502, encodeId=f5b31e845027b, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Sat Oct 15 05:05:44 CST 2022, time=2022-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878522, encodeId=cf8018e852248, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Thu Nov 24 05:05:44 CST 2022, time=2022-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754961, encodeId=314c1e54961a2, content=<a href='/topic/show?id=bf6093140d4' target=_blank style='color:#2F92EE;'>#路易体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93140, encryptionId=bf6093140d4, topicName=路易体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=576436807451, createdName=longerg, createdTime=Fri Feb 17 21:05:44 CST 2023, time=2023-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013883, encodeId=a69420138833f, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Mar 24 16:05:44 CST 2023, time=2023-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077687, encodeId=11f420e76871a, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Thu Dec 08 18:05:44 CST 2022, time=2022-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738120, encodeId=097e1e3812015, content=<a href='/topic/show?id=e10b600329' target=_blank style='color:#2F92EE;'>#disorders#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6003, encryptionId=e10b600329, topicName=disorders)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Mon Oct 03 23:05:44 CST 2022, time=2022-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402848, encodeId=66fd1402848c3, content=<a href='/topic/show?id=60ca9e761ce' target=_blank style='color:#2F92EE;'>#阿尔兹海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97761, encryptionId=60ca9e761ce, topicName=阿尔兹海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be952422716, createdName=habb, createdTime=Sat May 28 12:05:44 CST 2022, time=2022-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487161, encodeId=6ee3148e1614c, content=<a href='/topic/show?id=5b8d2299977' target=_blank style='color:#2F92EE;'>#临床表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22999, encryptionId=5b8d2299977, topicName=临床表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70ff8274322, createdName=hukaixun, createdTime=Sat May 28 12:05:44 CST 2022, time=2022-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535334, encodeId=7e7d153533453, content=<a href='/topic/show?id=099f9020145' target=_blank style='color:#2F92EE;'>#表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90201, encryptionId=099f9020145, topicName=表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6412593156, createdName=tastas, createdTime=Sat May 28 12:05:44 CST 2022, time=2022-05-28, status=1, ipAttribution=)]
    2023-02-17 longerg
  4. [GetPortalCommentsPageByObjectIdResponse(id=1784502, encodeId=f5b31e845027b, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Sat Oct 15 05:05:44 CST 2022, time=2022-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878522, encodeId=cf8018e852248, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Thu Nov 24 05:05:44 CST 2022, time=2022-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754961, encodeId=314c1e54961a2, content=<a href='/topic/show?id=bf6093140d4' target=_blank style='color:#2F92EE;'>#路易体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93140, encryptionId=bf6093140d4, topicName=路易体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=576436807451, createdName=longerg, createdTime=Fri Feb 17 21:05:44 CST 2023, time=2023-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013883, encodeId=a69420138833f, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Mar 24 16:05:44 CST 2023, time=2023-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077687, encodeId=11f420e76871a, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Thu Dec 08 18:05:44 CST 2022, time=2022-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738120, encodeId=097e1e3812015, content=<a href='/topic/show?id=e10b600329' target=_blank style='color:#2F92EE;'>#disorders#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6003, encryptionId=e10b600329, topicName=disorders)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Mon Oct 03 23:05:44 CST 2022, time=2022-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402848, encodeId=66fd1402848c3, content=<a href='/topic/show?id=60ca9e761ce' target=_blank style='color:#2F92EE;'>#阿尔兹海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97761, encryptionId=60ca9e761ce, topicName=阿尔兹海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be952422716, createdName=habb, createdTime=Sat May 28 12:05:44 CST 2022, time=2022-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487161, encodeId=6ee3148e1614c, content=<a href='/topic/show?id=5b8d2299977' target=_blank style='color:#2F92EE;'>#临床表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22999, encryptionId=5b8d2299977, topicName=临床表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70ff8274322, createdName=hukaixun, createdTime=Sat May 28 12:05:44 CST 2022, time=2022-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535334, encodeId=7e7d153533453, content=<a href='/topic/show?id=099f9020145' target=_blank style='color:#2F92EE;'>#表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90201, encryptionId=099f9020145, topicName=表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6412593156, createdName=tastas, createdTime=Sat May 28 12:05:44 CST 2022, time=2022-05-28, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1784502, encodeId=f5b31e845027b, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Sat Oct 15 05:05:44 CST 2022, time=2022-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878522, encodeId=cf8018e852248, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Thu Nov 24 05:05:44 CST 2022, time=2022-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754961, encodeId=314c1e54961a2, content=<a href='/topic/show?id=bf6093140d4' target=_blank style='color:#2F92EE;'>#路易体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93140, encryptionId=bf6093140d4, topicName=路易体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=576436807451, createdName=longerg, createdTime=Fri Feb 17 21:05:44 CST 2023, time=2023-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013883, encodeId=a69420138833f, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Mar 24 16:05:44 CST 2023, time=2023-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077687, encodeId=11f420e76871a, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Thu Dec 08 18:05:44 CST 2022, time=2022-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738120, encodeId=097e1e3812015, content=<a href='/topic/show?id=e10b600329' target=_blank style='color:#2F92EE;'>#disorders#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6003, encryptionId=e10b600329, topicName=disorders)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Mon Oct 03 23:05:44 CST 2022, time=2022-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402848, encodeId=66fd1402848c3, content=<a href='/topic/show?id=60ca9e761ce' target=_blank style='color:#2F92EE;'>#阿尔兹海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97761, encryptionId=60ca9e761ce, topicName=阿尔兹海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be952422716, createdName=habb, createdTime=Sat May 28 12:05:44 CST 2022, time=2022-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487161, encodeId=6ee3148e1614c, content=<a href='/topic/show?id=5b8d2299977' target=_blank style='color:#2F92EE;'>#临床表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22999, encryptionId=5b8d2299977, topicName=临床表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70ff8274322, createdName=hukaixun, createdTime=Sat May 28 12:05:44 CST 2022, time=2022-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535334, encodeId=7e7d153533453, content=<a href='/topic/show?id=099f9020145' target=_blank style='color:#2F92EE;'>#表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90201, encryptionId=099f9020145, topicName=表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6412593156, createdName=tastas, createdTime=Sat May 28 12:05:44 CST 2022, time=2022-05-28, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1784502, encodeId=f5b31e845027b, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Sat Oct 15 05:05:44 CST 2022, time=2022-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878522, encodeId=cf8018e852248, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Thu Nov 24 05:05:44 CST 2022, time=2022-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754961, encodeId=314c1e54961a2, content=<a href='/topic/show?id=bf6093140d4' target=_blank style='color:#2F92EE;'>#路易体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93140, encryptionId=bf6093140d4, topicName=路易体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=576436807451, createdName=longerg, createdTime=Fri Feb 17 21:05:44 CST 2023, time=2023-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013883, encodeId=a69420138833f, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Mar 24 16:05:44 CST 2023, time=2023-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077687, encodeId=11f420e76871a, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Thu Dec 08 18:05:44 CST 2022, time=2022-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738120, encodeId=097e1e3812015, content=<a href='/topic/show?id=e10b600329' target=_blank style='color:#2F92EE;'>#disorders#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6003, encryptionId=e10b600329, topicName=disorders)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Mon Oct 03 23:05:44 CST 2022, time=2022-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402848, encodeId=66fd1402848c3, content=<a href='/topic/show?id=60ca9e761ce' target=_blank style='color:#2F92EE;'>#阿尔兹海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97761, encryptionId=60ca9e761ce, topicName=阿尔兹海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be952422716, createdName=habb, createdTime=Sat May 28 12:05:44 CST 2022, time=2022-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487161, encodeId=6ee3148e1614c, content=<a href='/topic/show?id=5b8d2299977' target=_blank style='color:#2F92EE;'>#临床表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22999, encryptionId=5b8d2299977, topicName=临床表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70ff8274322, createdName=hukaixun, createdTime=Sat May 28 12:05:44 CST 2022, time=2022-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535334, encodeId=7e7d153533453, content=<a href='/topic/show?id=099f9020145' target=_blank style='color:#2F92EE;'>#表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90201, encryptionId=099f9020145, topicName=表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6412593156, createdName=tastas, createdTime=Sat May 28 12:05:44 CST 2022, time=2022-05-28, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1784502, encodeId=f5b31e845027b, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Sat Oct 15 05:05:44 CST 2022, time=2022-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878522, encodeId=cf8018e852248, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Thu Nov 24 05:05:44 CST 2022, time=2022-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754961, encodeId=314c1e54961a2, content=<a href='/topic/show?id=bf6093140d4' target=_blank style='color:#2F92EE;'>#路易体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93140, encryptionId=bf6093140d4, topicName=路易体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=576436807451, createdName=longerg, createdTime=Fri Feb 17 21:05:44 CST 2023, time=2023-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013883, encodeId=a69420138833f, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Mar 24 16:05:44 CST 2023, time=2023-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077687, encodeId=11f420e76871a, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Thu Dec 08 18:05:44 CST 2022, time=2022-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738120, encodeId=097e1e3812015, content=<a href='/topic/show?id=e10b600329' target=_blank style='color:#2F92EE;'>#disorders#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6003, encryptionId=e10b600329, topicName=disorders)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Mon Oct 03 23:05:44 CST 2022, time=2022-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402848, encodeId=66fd1402848c3, content=<a href='/topic/show?id=60ca9e761ce' target=_blank style='color:#2F92EE;'>#阿尔兹海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97761, encryptionId=60ca9e761ce, topicName=阿尔兹海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be952422716, createdName=habb, createdTime=Sat May 28 12:05:44 CST 2022, time=2022-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487161, encodeId=6ee3148e1614c, content=<a href='/topic/show?id=5b8d2299977' target=_blank style='color:#2F92EE;'>#临床表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22999, encryptionId=5b8d2299977, topicName=临床表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70ff8274322, createdName=hukaixun, createdTime=Sat May 28 12:05:44 CST 2022, time=2022-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535334, encodeId=7e7d153533453, content=<a href='/topic/show?id=099f9020145' target=_blank style='color:#2F92EE;'>#表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90201, encryptionId=099f9020145, topicName=表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6412593156, createdName=tastas, createdTime=Sat May 28 12:05:44 CST 2022, time=2022-05-28, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1784502, encodeId=f5b31e845027b, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Sat Oct 15 05:05:44 CST 2022, time=2022-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878522, encodeId=cf8018e852248, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Thu Nov 24 05:05:44 CST 2022, time=2022-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754961, encodeId=314c1e54961a2, content=<a href='/topic/show?id=bf6093140d4' target=_blank style='color:#2F92EE;'>#路易体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93140, encryptionId=bf6093140d4, topicName=路易体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=576436807451, createdName=longerg, createdTime=Fri Feb 17 21:05:44 CST 2023, time=2023-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013883, encodeId=a69420138833f, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Mar 24 16:05:44 CST 2023, time=2023-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077687, encodeId=11f420e76871a, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Thu Dec 08 18:05:44 CST 2022, time=2022-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738120, encodeId=097e1e3812015, content=<a href='/topic/show?id=e10b600329' target=_blank style='color:#2F92EE;'>#disorders#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6003, encryptionId=e10b600329, topicName=disorders)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Mon Oct 03 23:05:44 CST 2022, time=2022-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402848, encodeId=66fd1402848c3, content=<a href='/topic/show?id=60ca9e761ce' target=_blank style='color:#2F92EE;'>#阿尔兹海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97761, encryptionId=60ca9e761ce, topicName=阿尔兹海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be952422716, createdName=habb, createdTime=Sat May 28 12:05:44 CST 2022, time=2022-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487161, encodeId=6ee3148e1614c, content=<a href='/topic/show?id=5b8d2299977' target=_blank style='color:#2F92EE;'>#临床表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22999, encryptionId=5b8d2299977, topicName=临床表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70ff8274322, createdName=hukaixun, createdTime=Sat May 28 12:05:44 CST 2022, time=2022-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535334, encodeId=7e7d153533453, content=<a href='/topic/show?id=099f9020145' target=_blank style='color:#2F92EE;'>#表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90201, encryptionId=099f9020145, topicName=表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6412593156, createdName=tastas, createdTime=Sat May 28 12:05:44 CST 2022, time=2022-05-28, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1784502, encodeId=f5b31e845027b, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Sat Oct 15 05:05:44 CST 2022, time=2022-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878522, encodeId=cf8018e852248, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Thu Nov 24 05:05:44 CST 2022, time=2022-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754961, encodeId=314c1e54961a2, content=<a href='/topic/show?id=bf6093140d4' target=_blank style='color:#2F92EE;'>#路易体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93140, encryptionId=bf6093140d4, topicName=路易体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=576436807451, createdName=longerg, createdTime=Fri Feb 17 21:05:44 CST 2023, time=2023-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013883, encodeId=a69420138833f, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Mar 24 16:05:44 CST 2023, time=2023-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077687, encodeId=11f420e76871a, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Thu Dec 08 18:05:44 CST 2022, time=2022-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738120, encodeId=097e1e3812015, content=<a href='/topic/show?id=e10b600329' target=_blank style='color:#2F92EE;'>#disorders#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6003, encryptionId=e10b600329, topicName=disorders)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Mon Oct 03 23:05:44 CST 2022, time=2022-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402848, encodeId=66fd1402848c3, content=<a href='/topic/show?id=60ca9e761ce' target=_blank style='color:#2F92EE;'>#阿尔兹海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97761, encryptionId=60ca9e761ce, topicName=阿尔兹海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be952422716, createdName=habb, createdTime=Sat May 28 12:05:44 CST 2022, time=2022-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487161, encodeId=6ee3148e1614c, content=<a href='/topic/show?id=5b8d2299977' target=_blank style='color:#2F92EE;'>#临床表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22999, encryptionId=5b8d2299977, topicName=临床表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70ff8274322, createdName=hukaixun, createdTime=Sat May 28 12:05:44 CST 2022, time=2022-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535334, encodeId=7e7d153533453, content=<a href='/topic/show?id=099f9020145' target=_blank style='color:#2F92EE;'>#表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90201, encryptionId=099f9020145, topicName=表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6412593156, createdName=tastas, createdTime=Sat May 28 12:05:44 CST 2022, time=2022-05-28, status=1, ipAttribution=)]
    2022-05-28 tastas

相关资讯

iPSC疗法、新靶点、单细胞测序,帕金森病最新研究进展解读

帕金森病的治疗和诊断一直是十分热门的研究领域,最近帕金森病领域有了一些新的突破。通过这篇文章,我们一起了解下帕金森病领域的一些新发现、新进展。

JPD:苍白球内侧的神经变性,与步态冻结中多巴反应,关系密切

GPi的结构完整性作为FOG的多巴反应的相关因素

Neurology:帕金森病患者中运动和非运动症状与健康相关生活质量的关系

近日,研究人员发现潜在的可治疗的运动和非运动症状,特别是神经精神症状,是PwPD患者HRQOL变化的主要原因。这一发现为临床医生的干预和未来的症状管理研究提供了目标,以优化帕金森病患者的HRQOL。

Neurology:小脑性共济失调和帕金森病患者的冲动性特征

患有小脑性共济失调(CA)的人会出现冲动的行为症状。不同于帕金森患者,CA患者的冲动由非计划性特征驱动。这表明小脑和基底节可能以不同的方式控制冲动行为,小脑以一种特定领域的方式参与冲动的大脑回路。

Movment Disorders:帕金森氏征,7T MRI蓝斑核完整性与帕金森病患者的冷漠和认知有关

去甲肾上腺素能治疗策略在解决神经退行性疾病的跨诊断认知和行为特征方面有潜力。

拓展阅读

综述|重复经颅磁刺激治疗帕金森病言语障碍研究进展

rTMS在PD言语障碍的治疗中取得了良好的效果,但目前研究的数量较少,未来还需要更多大规模和大样本量的随机对照试验来进一步验证和支持其效果。

Lancet Neurol:帕金森病新分类模型

该模型被称为SynNeurGe(发音为“synergy”),旨在捕捉帕金森病的异质性,并帮助研究该疾病的潜在生物学。

疑难探究:当帕金森病遇到OH如何与MSA-P 鉴别?

MSA患者的认知缺陷仍未得到很好的描述,OH是否会像PD一样增加MSA患者未来痴呆的风险仍有待评估。

帕金森病:认知障碍From PD-MCI to PDD

帕金森病的认知能力下降与胆碱能系统退化有关,这可以使用基底前脑体积的结构性MRI标记物和皮质胆碱能活性的PET测量在体内进行评估。

帕金森病:睡眠障碍与昼夜节律

帕金森病是一种进行性神经退行性疾病,具有运动和非运动症状,包括睡眠功能障碍。非运动症状对生活质量有负面影响,并且通常比运动症状更令人烦恼。

European Radiology:使用多模态PET/MRI放射组学识别帕金森病和多系统萎缩

放射组学是指从医学影像中高通量提取丰富的影像信息,以辅助医生做出最准确的诊断。现阶段,放射组学已广泛应用于肿瘤学研究,如肿瘤的诊断、分级、疗效评估、预后预测等。

2024 NICE 诊断指南:帕金森病远程监测设备 [DG51]

英国国家卫生与临床优化研究所(NICE,National Institute for Health and Clinical Excellence) · 2024-01-25

2023 NICE 技术鉴定指南:左旋多巴/卡比多巴组合治疗伴有运动症状的晚期帕金森病[TA934]

英国国家卫生与临床优化研究所(NICE,National Institute for Health and Clinical Excellence) · 2023-11-29

帕金森病患者睡眠障碍评估与护理干预的最佳证据总结

浙江中医药大学护理学院 · 2023-08-10

早中期帕金森病患者运动管理的最佳证据总结

山东第一医科大学附属省立医院老年神经内科 · 2023-05-10